|Bid||16.94 x 1100|
|Ask||16.95 x 800|
|Day's Range||16.80 - 17.60|
|52 Week Range||9.80 - 31.56|
|Beta (5Y Monthly)||1.94|
|PE Ratio (TTM)||16.87|
|Earnings Date||Aug 10, 2016 - Aug 15, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Mar 12, 2020|
|1y Target Est||19.03|
TALTZ is now approved to treat patients across the axSpA spectrum, including ankylosing spondylitis and non-radiographic axSpA TORONTO, Oct. 19, 2020 /CNW/ - On October 14, 2020, Health Canada approved TALTZ® for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have responded inadequately to, or are intolerant to conventional therapy.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
(NYSE: CAE) (TSX: CAE) – CAE today announced that it has become carbon neutral as of September 28, 2020, proudly becoming the first Canadian aerospace company to reach this goal. The company has achieved carbon neutrality by continuing to reduce its own emissions and by making investments in projects that offset its remaining annual carbon emissions.